Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVIRNASDAQ:CGCNASDAQ:MNPRNASDAQ:RPHM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVIRAtea Pharmaceuticals$2.76+1.8%$2.94$2.60▼$4.15$236.20M0.17302,819 shs408,236 shsCGCCanopy Growth$1.35+4.3%$1.13$0.77▼$11.95$247.30M0.796.02 million shs4.11 million shsMNPRMonopar Therapeutics$42.37+8.4%$36.64$1.72▼$54.30$259.09M1.11359,126 shs14,340 shsRPHMReneo Pharmaceuticals$1.82$1.64$0.98▼$9.21$60.84M0.21250,384 shs437,523 shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVIRAtea Pharmaceuticals-3.39%-8.31%-2.70%-12.74%-31.35%CGCCanopy Growth+0.78%-6.52%+38.64%-53.60%-86.39%MNPRMonopar Therapeutics-1.92%-8.19%+32.90%-18.50%+907.77%RPHMReneo Pharmaceuticals0.00%0.00%0.00%0.00%+4.60%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAVIRAtea Pharmaceuticals2.8836 of 5 stars3.33.00.00.02.42.51.3CGCCanopy Growth2.4865 of 5 stars2.54.00.00.01.70.01.3MNPRMonopar Therapeutics2.9246 of 5 stars3.45.00.00.02.72.50.0RPHMReneo PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVIRAtea Pharmaceuticals 2.50Moderate Buy$6.00117.39% UpsideCGCCanopy Growth 1.00Sell$2.0048.70% UpsideMNPRMonopar Therapeutics 2.75Moderate Buy$55.3330.60% UpsideRPHMReneo Pharmaceuticals 2.00Hold$1.50-17.58% DownsideCurrent Analyst Ratings BreakdownLatest RPHM, AVIR, MNPR, and CGC Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/11/2025AVIRAtea PharmaceuticalsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$6.20 ➝ $6.004/2/2025MNPRMonopar TherapeuticsJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold4/1/2025MNPRMonopar TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00 ➝ $40.003/19/2025MNPRMonopar TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight$76.003/7/2025AVIRAtea PharmaceuticalsWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform(Data available from 5/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVIRAtea PharmaceuticalsN/AN/AN/AN/A$6.65 per shareN/ACGCCanopy Growth$276.75M0.89N/AN/A$2.72 per share0.49MNPRMonopar TherapeuticsN/AN/AN/AN/A$1.88 per shareN/ARPHMReneo PharmaceuticalsN/AN/AN/AN/A$2.66 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVIRAtea Pharmaceuticals-$135.96M-$2.00N/AN/AN/AN/A-34.90%-32.38%5/12/2025 (Estimated)CGCCanopy Growth-$487.23M-$3.80N/AN/AN/A-156.98%-56.52%-24.18%5/29/2025 (Estimated)MNPRMonopar Therapeutics-$8.40M-$3.60N/AN/AN/AN/A-107.21%-87.57%5/8/2025 (Estimated)RPHMReneo Pharmaceuticals-$77.39M-$2.17N/AN/AN/AN/A-62.52%-56.36%N/ALatest RPHM, AVIR, MNPR, and CGC EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/29/2025Q4 2025CGCCanopy Growth-$0.28N/AN/AN/A$71.84 millionN/A5/12/2025Q1 2025AVIRAtea Pharmaceuticals-$0.41N/AN/AN/AN/AN/A5/8/2025N/AMNPRMonopar Therapeutics-$0.65N/AN/AN/AN/AN/A3/31/2025Q4 2024MNPRMonopar Therapeutics-$0.36-$2.23-$1.87-$2.23N/AN/A3/6/2025Q4 2024AVIRAtea Pharmaceuticals-$0.35-$0.40-$0.05-$0.40N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAVIRAtea PharmaceuticalsN/AN/AN/AN/AN/ACGCCanopy GrowthN/AN/AN/AN/AN/AMNPRMonopar TherapeuticsN/AN/AN/AN/AN/ARPHMReneo PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVIRAtea PharmaceuticalsN/A19.3319.33CGCCanopy Growth0.743.522.58MNPRMonopar TherapeuticsN/A5.415.41RPHMReneo PharmaceuticalsN/A57.8657.86Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVIRAtea Pharmaceuticals86.67%CGCCanopy Growth3.33%MNPRMonopar Therapeutics1.83%RPHMReneo Pharmaceuticals90.98%Insider OwnershipCompanyInsider OwnershipAVIRAtea Pharmaceuticals17.80%CGCCanopy Growth1.30%MNPRMonopar Therapeutics34.90%RPHMReneo Pharmaceuticals17.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVIRAtea Pharmaceuticals7085.58 million69.43 millionOptionableCGCCanopy Growth3,150183.87 million153.39 millionOptionableMNPRMonopar Therapeutics106.12 million3.97 millionNot OptionableRPHMReneo Pharmaceuticals3033.43 million27.44 millionOptionableRPHM, AVIR, MNPR, and CGC HeadlinesRecent News About These CompaniesOnkure Therapeutics Inc (OKUR)December 4, 2024 | investing.comCormorant Asset Management's Strategic Acquisition of Reneo Pharmaceuticals SharesOctober 11, 2024 | finance.yahoo.comDeep Track Capital's Strategic Investment in Reneo PharmaceuticalsOctober 11, 2024 | finance.yahoo.comCarlyle Group Inc. Reduces Stake in Reneo Pharmaceuticals Inc.October 10, 2024 | finance.yahoo.comReneo Pharmaceuticals: Navigating Financial Challenges and Corporate ChangesOctober 9, 2024 | finance.yahoo.comOnKure Announces Closing of Merger with Reneo Pharmaceuticals and Concurrent Private Placement of $65 MillionOctober 4, 2024 | globenewswire.comBaosheng Media Gr (NASDAQ:BAOS) Stock Quotes, Forecast and News SummaryOctober 3, 2024 | benzinga.comReneo Pharmaceuticals Announces Stockholder Approval of Merger with OnKureOctober 2, 2024 | globenewswire.comBraden Michael Leonard Acquires 29,600 Shares of Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) StockSeptember 27, 2024 | insidertrades.comBraden Michael Leonard Purchases 55,300 Shares of Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) StockSeptember 20, 2024 | insidertrades.comReneo Pharmaceuticals Inc (RPHM) Stock: More Resilient Than It AppearsSeptember 15, 2024 | bovnews.comColor Star Tech (NASDAQ:ADD) Stock Quotes, Forecast and News SummarySeptember 12, 2024 | benzinga.comReneo Pharmaceuticals insider buys shares worth over $380kAugust 16, 2024 | investing.comReneo Pharmaceuticals, Inc. (NASDAQ:RPHM) Major Shareholder Braden Michael Leonard Acquires 171,339 SharesAugust 15, 2024 | insidertrades.comRPHM Stock Earnings: Reneo Pharmaceuticals Misses EPS for Q2 2024August 13, 2024 | investorplace.comReneo Pharmaceuticals Reports Second Quarter 2024 Financial ResultsAugust 13, 2024 | globenewswire.comSTOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHMJune 26, 2024 | globenewswire.comSTOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHMJune 24, 2024 | prnewswire.comSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AAN, RPHM on Behalf of ShareholdersJune 21, 2024 | globenewswire.comSTOCKHOLDER INVESTIGATION: The M&A Class Action Firm Investigates Merger of Reneo Pharmaceuticals, Inc. - RPHMJune 21, 2024 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeRPHM, AVIR, MNPR, and CGC Company DescriptionsAtea Pharmaceuticals NASDAQ:AVIR$2.76 +0.05 (+1.85%) Closing price 04:00 PM EasternExtended Trading$2.76 0.00 (0.00%) As of 06:07 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.Canopy Growth NASDAQ:CGC$1.34 +0.06 (+4.26%) Closing price 03:59 PM EasternExtended Trading$1.33 -0.01 (-1.12%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.Monopar Therapeutics NASDAQ:MNPR$42.37 +3.27 (+8.36%) Closing price 04:00 PM EasternExtended Trading$40.40 -1.97 (-4.65%) As of 04:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.Reneo Pharmaceuticals NASDAQ:RPHMReneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases. The company's lead product candidate is REN001, a potent and selective agonist of the peroxisome proliferator-activated receptor delta that is in clinical development for genetic mitochondrial diseases comprising primary mitochondrial myopathies and long-chain fatty acid oxidation disorders. Reneo Pharmaceuticals, Inc. was incorporated in 2014 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Energy Transfer Undervalued or a Value Trap? Carvana’s Stock Price Rebound Shifts Into a Higher Gear Why Investors Should Be Careful About AMC's Bitcoin Dreams Alphabet Slumps as Apple Eyes AI Search—Is the Sell-Off Overdone? Joby's Q1: Key Milestones Achieved as Path to Market Crystalizes Rockwell Automation: Tailwinds From Onshoring U.S. Production IBM's AI Offensive: Assessing IBM's Path to Renewed Growth Upwork's Earnings Beat Fuels Stock Rally—Is Freelancing Booming? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
